Edoardo Garbo

4 weeks ago | acsjournals.onlinelibrary.wiley.com | Francesco Passiglia |Francesco Pepe |Gianluca Russo |Edoardo Garbo

INTRODUCTION Recently, an exon 2 p.G12C Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutation was introduced in the arena of positive predictive biomarkers to be tested for treatment selection in patients with metastatic non-small cell lung cancer (NSCLC).1 Sotorasib is the first-in-class covalent off inhibitor, able to irreversibly lock the KRAS G12C–mutated protein in its inactive state, impairing the downstream oncogenic signaling pathways.2, 3 Based on the positive results from the...